Related references
Note: Only part of the references are listed.Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment
Christopher M. Rubino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme
Michael A. Pfaller et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis
William J. Weiss et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae
Mojgan Sabet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model
Mojgan Sabet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
Dongxu Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
Olga Lomovskaya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases
Ghady Haidar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects
David C. Griffith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects
Eric Wenzler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Meropenem Combined with RPX7009, a Novel beta-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens
Karen Bush
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Scott J. Hecker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Stormy waters ahead: global emergence of carbapenemases
Gopi Patel et al.
FRONTIERS IN MICROBIOLOGY (2013)
Epidemiological Expansion, Structural Studies, and Clinical Challenges of New beta-Lactamases from Gram-Negative Bacteria
Karen Bush et al.
ANNUAL REVIEW OF MICROBIOLOGY, VOL 65 (2011)
Comparative review of the carbapenems
George G. Zhanel et al.
DRUGS (2007)
Share Paper
